ClinicalTrials.gg
Active, not recruitingNCT06764303Updated Sep 23, 2025

A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

A Phase 2 interventional study of NTQ5082 100mg qd and NTQ5082 200mg qd in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Nanjing Chia-tai Tianqing Pharmaceutical. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Nanjing Chia-tai Tianqing Pharmaceutical (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 21 open to participants now, 29 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Planned enrollment
35th of 47
24 · median 40
Started
2025
with 11 others
Phase 2
13 of 51
4 open now
Primary completion
2025-07
later than 4 of 28 live
Registered
28th of 51
by date
Lead sponsor
3 of 51
Nanjing Chia-tai Tianqing Pharmaceutical

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 35th largest by planned enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 4 of the 28 other live ones, and was the 28th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

21 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

NTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old (including lower limit), gender not limited.
  2. According to the diagnostic criteria for PNH in the Chinese "Guidelines for the Diagnosis and Treatment of Rare Diseases" (2019 edition), subjects diagnosed with PNH have a red blood cell and/or granulocyte clone level of>10% within the 6 months prior to screening.
  3. I have not received complement inhibitor treatment in the past.
  4. Laboratory testing (local laboratory) shows that meets one of the following conditions: (1) screening period V1 and V2 (interval ≥ 7 days) hemoglobin\<100g/L; (2) If the subject receives red blood cell transfusion treatment for PNH related anemia during the screening period, they must meet the condition of hemoglobin\<100g/L at V1;
  5. Screening periods V1 and V2 (with an interval of ≥ 7 days) were used to detect blood lactate dehydrogenase (LDH) levels (local laboratory)>1.5 times the (ULN);
  6. Vaccination with ACYW135 meningococcal and pneumococcal vaccines (if previously administered, effective titers should be provided) at least 14 days prior to the initial administration of the study drug (defined as D1); If vaccinated within 14 days before D1, prophylactic antibiotic treatment should be given until at least 14 days after vaccination;
  7. Agree to use at least one effective measure during sexual intercourse with their partner from the time of signing the form until 4 weeks after the last administration, and not to participate in sperm or egg donation.
  8. Agree to sign the informed consent form and promise to comply with all regulations in the study.

Exclusion criteria

Exclusion Criteria:

  1. During the screening period, there was laboratory (local laboratory) evidence of bone marrow failure (reticulocyte count\<100 × 109/L, count\<30 × 109/L, or \<0.5 × 109/L).
  2. During the screening period, the laboratory (local laboratory) results showed or ALP>3 × and the researcher deemed it unsuitable to participate in the study.
  3. Prior to screening, the subject was receiving treatment with the following drugs, and the duration of treatment at the stable dose of the drug did not meet the following conditions: systemic use of for at least 4 weeks (≤ 15mg/day of prednisone or equivalent dose of corticosteroids); Iron supplements, vitamin B12, folic acid or androgens for at least 4 weeks; Vitamin K antagonists (such as warfarin) should be used for at least 4 weeks and the (INR) should be stable; Low molecular weight heparin and oral anticoagulants (such as aspirin, rivaroxaban, idoxaban, apixaban) for at least 4 weeks; Erythropoietin (ESA), hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI), or for at least 8 weeks.
  4. Previous history of bone marrow/hematopoietic stem cell or solid organ transplantation (such as heart, lung, kidney, liver).
  5. Individuals with a history of splenectomy or planning to undergo surgery during the trial period.
  6. Previous history of meningococcal infection or active systemic bacterial, viral, or fungal infection within 14 days prior to the first administration of the study drug (defined as D1) (at the discretion of the investigator).
  7. Patients with a history of malignant tumors within the past 5 years before screening, but those who have already been cured of local basal cell carcinoma of the skin, squamous cell carcinoma of the skin, papillary thyroid carcinoma, and cervical carcinoma in situ, are excluded.
  8. Known or suspected genetic complement deficiency or primary or severe secondary immunodeficiency.
  9. There is a history of kidney, heart, liver, lung, and other conditions that the researchers have determined are not suitable for participation in this study, including but not limited to the following: severe uncontrolled hypertension, severe kidney disease (such as \<30 mL/min/1.73m2), advanced heart disease ( IV grade), severe lung disease (such as severe pulmonary arterial hypertension (WHO IV grade), unstable thrombotic events, etc.
  10. Suffering from active (HBsAg positive and HBV-DNA>local laboratory detection limit), or (HCV antibody positive and HCV-RNA>local laboratory detection limit); Or tested positive for ; Or positive for Treponema pallidum antibody.
  11. Have received any type of attenuated within the previous 4 weeks of screening, or plan to receive any attenuated live vaccine during the research process.
  12. Participated in any other interventional clinical trials (including drug and device clinical trials) within the previous 4 weeks prior to screening.
  13. Suspect individuals who are allergic to the drug or any of its components.
  14. Pregnant and lactating female subjects.
  15. Any medical condition that the researcher determines may affect the patient's participation in the study, may increase significant risks to the safety of the subjects, or other situations that the researcher determines are not suitable for participation in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    100mg qd

    This group included 12 subjects, all of whom received NTQ5082 capsules 100mg qd administration

    Drug: NTQ5082 100mg qd

  • Experimental
    200mg qd

    This group included 12 subjects, all of whom received NTQ5082 capsules 200mg qd administration

    Drug: NTQ5082 200mg qd

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of subjects whose hemoglobin (Hb) levels continue to increase by ≥ 20 g/L compared to baseline

    Time frame: 12 Weeks

Secondary outcomes

  1. The proportion of subjects with Hb levels consistently ≥ 120 g/L

    Time frame: 12 Weeks

  2. The proportion of subjects who did not receive blood transfusion

    Time frame: 12 Weeks

  3. The number of red blood cell units transfused to the subjects receiving blood transfusion

    Time frame: 12 Weeks

  4. Changes in Hb compared to baseline

    Time frame: 12 Weeks

  5. Changes in reticulocyte count compared to baseline

    Time frame: 12 Weeks

  6. Changes in lactate dehydrogenase (LDH) compared to baseline

    Time frame: 12 Weeks

  7. Changes in total/indirect bilirubin compared to baseline

    Time frame: 12 Weeks

  8. Changes in conjugated hemoglobin compared to baseline

    Time frame: 12 Weeks

  9. Changes in free hemoglobin compared to baseline

    Time frame: 12 Weeks

  10. The proportion of subjects with LDH<1.5 × ULN

    Time frame: 12 Weeks

  11. Changes in Chronic Disease Treatment Functional Evaluation Fatigue (FACIT-F) Scale Score Compared to Baseline

    Time frame: 12 Weeks

  12. Changes in the size of PNH red blood cell clones

    Time frame: 12 Weeks

  13. Changes in the deposition of C3 complement protein fragments on PNH red blood cells

    Time frame: 12 Weeks

  14. NTQ5082 capsule PD related biomarker levels: complement pathway activity, plasma fragment Bb, and human soluble terminal complement complex (sC5b-9) levels.

    Time frame: 12 Weeks

  15. The Plasma concentration of NTQ5082 and metabolite NTQ5082-M in plasma under steady-state conditions (ss)

    Time frame: 12 Weeks

  16. The incidence of breakthrough hemolysis in clinical practice.

    Time frame: 12 Weeks

  17. The incidence of thromboembolic events.

    Time frame: 12 Weeks

  18. Incidence and severity of adverse events

    Time frame: 12 Weeks

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jul 2025, 5 months.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 5 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2024
First posted
Jan 8, 2025
StartActual
Jan 23, 2025
Primary completionActual
Jul 8, 2025
CompletionEst.
Jul 8, 2027
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06764303
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Jan 23, 2025
Primary completion
Jul 8, 2025
Completion
Jul 8, 2027 (estimated)
Last update
Sep 23, 2025

Study contacts

fengkui zhang
principal investigator · Hematology Hospital of the Chinese Academy of Medical Sciences
hongyan tong
principal investigator · First Affiliated Hospital of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NTQ5082

Start the discussion